VGLL3 (Vestigial-like family member 3) is a transcriptional cofactor belonging to the VGLL protein family, which shares structural homology with the Drosophila vestigial protein involved in wing development. In humans, VGLL3 is implicated in regulating gene expression by interacting with transcription factors, such as TEAD family members, to modulate pathways critical for cellular differentiation, tissue development, and homeostasis. It plays roles in muscle development, cell proliferation, and tissue regeneration, with emerging links to immune regulation and cancer progression. Dysregulation of VGLL3 has been associated with pathological conditions, including fibrosis, autoimmune diseases, and malignancies like melanoma and breast cancer, where its overexpression may drive tumor invasiveness or therapy resistance.
VGLL3 antibodies are immunological tools designed to detect and quantify VGLL3 protein levels in research applications. These antibodies are typically developed in host species (e.g., rabbit, mouse) using immunogenic peptides or recombinant protein fragments. They enable the study of VGLL3's expression patterns, subcellular localization (nuclear/cytoplasmic), and interactions via techniques like Western blotting, immunohistochemistry, immunofluorescence, or co-immunoprecipitation. Validated antibodies are essential for exploring VGLL3's mechanistic roles in development and disease, particularly its crosstalk with Hippo, TGF-β, or Wnt signaling pathways. Specificity is confirmed using knockout controls or siRNA-mediated knockdown. Commercial VGLL3 antibodies vary in clonality, epitope targets, and applications, requiring careful validation for experimental reproducibility.